Explore ViiV Healthcare
David Redfern is the Chairman of ViiV Healthcare’s Board. David was appointed as GSK’s Chief Strategy Officer in May 2008 and is responsible for proactive exploration of new business opportunities, strategic planning and dermatology. He is a member of the GSK Corporate Executive Team. Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical businesses in Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and Switzerland. David also had overall responsibility for the European HIV business from 2006 to 2008. David joined the company in 1994 from PricewaterhouseCoopers, where he managed a portfolio of audit clients and corporate transactions. He began his career with GSK as Corporate Accounts Manager, and spent 4 years in the Corporate Development team before being appointed Finance Director of European Pharmaceuticals in 1999. He was appointed Senior Vice President & Area Director, Central Europe in 2003, where he successfully led the Central Europe markets through their transition into the EU, and Northern Europe in 2005. David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.
Deborah Waterhouse became Chief Executive Officer of ViiV Healthcare on 1st April 2017. She has been CEO Designate since 1st January 2017.
Deborah joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business. She brings a wealth of experience to ViiV Healthcare having lived and worked in Europe, Asia and the USA, and a strong track record of performance in both specialty and primary care. Deborah led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma
Doug Giordano is currently a Senior Vice President in Pfizer’s Worldwide Business Development Group, responsible for leading the evaluation, negotiation and execution of product licensing, partnerships and M&A transactions. Over the past six years, Doug has led teams responsible for Pfizer acquisitions and product licensing transactions including Pfizer’s acquisitions of Wyeth, Icagen, Excaliard, King Pharmaceuticals, FoldRx, Coley, CovX, Encysive and Serenex, and product collaborations announced with various partners including Hisun, Mylan, GlycoMimetics, Bausch & Lomb and Teuto.
Before joining Pfizer’s Worldwide Business Development group in 2007, Doug held positions of increasing responsibility within Pfizer’s US Pharmaceuticals commercial strategy and business development team. Doug has been a key contributor to a variety of Pfizer transactions and a variety of innovative US commercialization initiatives including the creation and launch of the Pfizer/Microsoft/IBM collaboration, Amicore and the launch of the Pfizer for Living ShareCard andPfizer Helpful Answers programs.
Before his US pharmaceuticals operating role, Doug worked in a mergers and acquisitions role within Pfizer’s Medical Technology Group -- playing a key role in Pfizer’s acquisitions, technology licensing and divestiture activity within medtech. Prior to his role with the Medical Technology Group, Doug held positions within Pfizer’s US Pharmaceutical Group in finance and global manufacturing.
Prior to joining Pfizer, Doug was a consultant at Booz, Allen & Hamilton.
Doug holds a Bachelor’s Degree in Biomedical Engineering from Duke University and an M.B.A. degree from Cornell University’s Johnson School of Business.
Luke joined GSK as President, Global Pharmaceuticals in September 2017. He is a member of the GSK Corporate Executive Team and a Board Member for ViiV Healthcare.
At GSK, he is responsible for commercialising a portfolio of medicines and vaccines with annual sales of more than £20 billion and operations in over 100 markets.
His previous role was Executive Vice President of AstraZeneca’s European business and, prior to that, Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.
Luke joined AstraZeneca from Roche, where he was Regional Vice President Asia Pacific for the Pharmaceuticals Division. Before then, he held roles of increasing seniority at Sanofi-Aventis in Asia and the US. He also co-led the US integration of Sanofi and Aventis. Prior to that, he held general management roles in Thailand and New Zealand, following his entry into the industry in Australia.
He holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.
Dr John Keller joined Shionogi Inc. in July of 2010 and was appointed as President and Chief Executive Officer and as a member of the Shionogi Inc. Board of Directors in April 2011.
Immediately prior to joining Shionogi, John was a Partner in SR One, the venture capital group of GlaxoSmithKline. Previously, John served as Executive Vice President and Chief Business Officer of Incyte Corporation, playing a key role in its transformation into a drug discovery and development company and establishing its first major corporate alliance after that transformation. Before Incyte, John had a 16 year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development. In that role, he structured numerous licensing agreements with a broad range of partners worldwide, including the agreements originally establishing the Shionogi-GSK (later Shionogi-ViiV Healthcare) joint venture. Earlier positions encompassed R&D strategy, technology licensing, alliance management, public policy, project management, and drug discovery research.
John holds a Ph.D. in microbiology from Rutgers University and a Bachelors degree in biology from Johns Hopkins University.
Dr. Rod MacKenzie is Executive Vice President, Chief Development Officer for Pfizer. Rod is responsible for the development and advancement of Pfizer’s pipeline of medicines in several therapeutic areas, including cardiovascular and metabolic disease, inflammation and immunology, neuroscience and pain, oncology and rare disease. He serves on the corporate Portfolio Strategy and Investment Committee and is a member of Pfizer’s Executive Leadership Team.
Rod began his career at Pfizer as a Research Scientist and worked in many medicinal chemistry programs across various therapeutic areas. Rod is the co-inventor of darifenacin (EnablexTM). He has held numerous leadership positions at Pfizer, including Head of PharmaTherapeutics Research and Development; Senior Vice President, Head of Worldwide Research; and Senior Vice President, Head of Drug Safety R&D and Comparative Medicine.
Rod graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his PhD at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York working in the area of molecular recognition.
Regis Simard is a Mechanical Engineer and also holds an MBA. He has held senior management positions in the Electronic and Tech industries (Sony, Konica-Minolta) and in the Healthcare and Medical devices industries (Covidien) where he gained valuable experience working with Japan, China, UK and France.
Regis joined GlaxoSmithKline in 2005 as Site Director at the GSK France plant at Notre Dame de Bondeville, then moved to GSK House UK to lead the Antibiotics and Latina Manufacturing cluster.
In January 2011, Regis was appointed Commercial Partner Emerging Markets & Asia Pacific and in January 2013 Regis was appointed to Senior Vice President /Head of Europe and EMAP Pharma Supply.
Regis moved into his latest role as Senior Vice President, Global Pharma Manufacturing (GMS) in January 2017. This position includes overseeing 17 factories and 10,000 employees globally, plus GMS global planning, and two franchise supply chains covering speciality and respiratory. Regis is also a member of the Supply Chain Executive team.
Specialties: Leadership. Manufacturing. Supply strategy. Business Development. Lean & 6 Sigma. People Development.
Diverse and broad experience of manufacturing, leadership to distil complexity and convey clear strategic direction, high levels of commerciality and customer/patient focus, incisive and focused when it comes to driving delivery, strong interest in people development
He is also a certified Six Sigma Black Belt.
KATE KNOBIL, MD
Chief Medical Officer
Dr. Kate Knobil was appointed Chief Medical Officer for GSK in October 2017.
Previous to this role, Dr. Knobil was Chief Medical Officer, Pharmaceuticals in November 2015, comprising Global Clinical Safety and Pharmacovigilance, Value Evidence and Outcomes (VEO), and the Medical Groups in the Respiratory and Specialty Franchises, as well as within Classic and Established Products. Together, these groups work together to understand the current and future needs of patients, clinicians and healthcare systems to generate and communicate evidence that informs on the benefits, risks, and overall value of our medicines.
Previous to this role, Dr. Knobil was SVP, VEO with global accountability for delivering the evidence to support the value of GSK medicines for patients, healthcare providers, and payers. She also had responsibility for the Real World Evidence Strategy for GSK.
Kate is a physician with extensive experience in pharmaceutical development. She completed her Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School, where she obtained an NIH grant to study the regulation of inflammatory genes after influenza virus infection. She joined GSK in 1997 to lead clinical development in the US for Respiratory medicines. International assignments first took her to the UK in 2005 to lead the European Respiratory Clinical Team, and then to China in 2010 to build the late stage clinical development capability across therapy areas.